The p53 transcription factor is either latent or activated through multi-site phosphorylation and acetylation of the negative regulatory region in its C-terminal domain (CTD) 1 . How CTD modifications activate p53 binding to target DNA sequences via its core domain is still unknown. It has been proposed that nonmodified CTD interacts either with the core domain or with DNA preventing binding of the core domain to DNA and that the fragments of the CTD regulatory region activate p53 by interfering with these interactions. We here characterized the sequence-and target-specificity of p53 activation by CTD fragments, interaction of activating peptides with p53 and target DNA, and interactions of "latent" p53 with DNA by a band shift assay and by fluorescence correlation spectroscopy. In addition to CTD fragments, several long basic peptides activated p53 and also transcription factor YY1. These peptides and CTD aggregated target DNA but apparently did not interact with p53. The potency to aggregate DNA correlated with the ability to activate p53, suggesting that p53 binds to target sequences upon interactions with tightly packed DNA in aggregates. "Latent" fulllength p53 dissociated DNA aggregates via its core and CTD, and this effect was potentiated by GTP. "Latent" p53 also formed complexes via both its core and CTD with long non-target DNA molecules. Such p53-DNA interactions may occur if "latent" p53 binding to DNA via CTD prevents the interaction of the core domain with target DNA sites but not with nonspecific DNA sequences.
INTRODUCTION
The p53 tumor suppressor protein is a latent transcription factor that is activated by various forms of cellular stress including DNA damage. Activation of p53 binding to target DNA sequences and, consequently, p53-dependent transcription is controlled by the negative regulatory region in the CTD of p53, which includes amino acids 361-382. Post-translational modifications of amino acid residues in this region through phosphorylation activate sequence-specific DNA binding. Acetylation of several C-terminal lysines by p300/CBP/PCAF, recruited through phosphorylation of the distant N-terminal serines, critically regulates the site-specific DNA-binding function of p53 (for reviews, see 1-3).
p53 exists in vitro in a latent form that cannot bind to p53 responsive DNA elements (4) . Deletion of the critical regulatory region in CTD, the C-terminal 30 amino acid fragment, results in p53 activation for sequence-specific DNA binding.
Furthermore, binding of the monoclonal antibody PAb421 to this region activates p53 sequence-specific DNA binding and triggers the transcriptional activity of p53 in vivo (4) .
The mechanism of the CTD-mediated inhibition of p53 sequence-specific DNA binding is not understood. It has been proposed that by intramolecular interaction with the p53 DNA-binding core, CTD allosterically locks the p53 molecule in a state latent for binding to DNA (4) . In accordance with this model, core domain in vitro (5, 6) . Activation of latent p53 by peptides derived from CTD has been reported to be sequence-specific since neither mutant p53(361-382) peptides nor peptides derived from the N-terminal p53 domain activate p53 or demonstrate only weak activity (4, 5, 7) . CTD also shows target specificity since it did not influence the interaction of SRF and GAL4-VP16 proteins with DNA (8) .
The overlap of the regulatory region in CTD, which is rich in basic amino acids, with the second DNA-binding site in the p53 molecule is the key feature of the steric model (9, 10) . This model postulates that p53 binds to genomic DNA via CTD and this binding prevents the interaction of the core domain with target sequences in gene promoters. The steric model is supported by the fact that long non-specific DNA molecules inhibit sequence-specific binding of the full-length p53 to DNA but shows no effect on p53 with deletion of the CTD regulatory sequence (9, 10) .
To gain insight into the mechanism of p53 latency, the sequence-and target-specificity of p53 activation by CTD fragments and the interactions of activating peptides with p53 and DNA were characterized. A conventional band shift assay was used to characterize p53 binding to DNA whereas fluorescence correlation spectroscopy (FCS) was applied to follow the interactions of activating peptides with p53 and DNA. The high sensitivity of FCS ( Fig. 1; refs. [11] [12] [13] [14] [15] allows analysis of such interactions and their nature even if they are weak in a reaction mixture. DNA molecules unexpectedly formed aggregates in the presence of the CTD fragment and other activating peptides. Our findings suggest that p53 is activated for binding to target DNA sites when it interacts with juxtaposed DNA molecules in DNA aggregates via both its core and CTD. Thus, CTD, when it binds to DNA, may prevent the interaction of the core domain of the full-length p53 with target, but not with non-target DNA sequences. This hypothesis seems to unify the previously postulated steric and allosteric models.
EXPERIMENTAL PROCEDURES
Plasmids, proteins and peptides. The plasmid encoding human wild-type p53, GST-human wild-type p53 fusion protein, the deletion fusion proteins GSTp53(1-100), GST-p53(99-307), GST-p53(320-393) and GST-p53∆30, the mutant fusion proteins GST-p53His273 and GST-p53Trp248 have been described elsewhere (5, (16) (17) (18) . The PG and MG fragments with 13 copies of consensus and 15 copies of mutant sites, respectively, were obtained by digestion of the PG-CAT and MG-CAT plasmids with HindIII/EcoRI. The RD fragment was cut from the pRC/CMV-Dyn plasmid. Plasmid DNA and oligonucleotides were purified by the Qiagen kit (Hilden, Germany) and polyacrylamide-urea gel electrophoresis, respectively, and their concentrations were determined from their absorbance at 260 nm and extinction coefficients calculated from nucleotide composition. p53 proteins were produced in E.coli, purified as outlined earlier and quantitated by Coomassie blue or silver staining following SDS-polyacrylamide (Mountain View, CA) and penta-L-Lysine and poly-L-Lysine were purchased from Bachem (Bubendorf, Switzerland). Eight CTD fragments (22mers) spanning CTD residues 337-393 with 14 residue overlap including p53(361-382) (GSRAHSSHLKSKKGQSTRHKK) were described earlier (18) .
DNA binding assays. Binding of p53 to specific sequences was performed as described earlier (4, 18) in the presence of 2 mM MgCl 2 . 1 nM 32 P-labeled 30mer BC oligonucleotides containing five adjacent copies of p53 consensus pentamer binding site and GST-p53 protein (35 nM of monomer) were incubated in the absence or in the presence of 25 nM of non-specific competitor poly(dIdC). p53 proteins binding to long 32 P-end-labelled DNA was described earlier (17) . AP-1, NF-κB, YY1 and protein Ku were assayed in nuclear extracts from SH-SY5Y cells and YY1 -with purified protein as described earlier (19, 20) .
Fluorescent compounds. BD with the C-terminal Cys-amide extension was synthesized and labeled with tetramethylrhodamine-5-iodoacetamide (Rh; Molecular Probes Europe BV, Netherlands) according to the manufacturer´s instructions. The Rh-BD was isolated on an analytical Nucleosil 120-3 C18 RP-HPLC column (Macherey-Nagel), lyophilized and the powder was weighed and used for preparation of solutions. The identity of the purified labeled peptide was confirmed by plasma desorption mass spectrometry. The purity of the peptide was > 90%. 
where the brackets describe the time average and <I> the mean fluorescence intensity (21, 22 ).
In our experiments fluorescence intensity fluctuations δI(t) occurring in a volume element of 0.2 fl with halfaxes ω=0.25 µm and z=1.25 µm are correlated (21, 22) , and for calculation of parameters of the autocorrelation function G(τ) the non-linear least-square minimization is used (23). The intensity autocorrelation function for 3D diffusion (13) of the unbound Rh-BD or Rh´-SO and bound Rh-BD or Rh´-SO is given by:
N is the number of molecules, τ G t 
RESULTS
Activation of p53 binding to specific DNA sequences by basic peptidesSequence-specificity of peptide effects on p53 binding to DNA was studied in a band shift assay. As previously described (18) , the GST-wild-type p53 protein remained latent in the absence of any DNA competitor ( showing that YY1 is present in the complex (lane 13) whereas other antibodies or C20 antibodies preincubated with a blocking peptide (lanes 11,12) failed to inhibit YY1 activation.
To determine whether the basic segment within the p53 protein is able to activate YY1, the effects of the full-length p53 and p53 domains on the YY1
DNA-binding activity were compared. GST-wild-type p53 at a low concentration Table 1 ). Poly-L-Lysine aggregated DNA at 3-and 20-fold lower molar concentrations compared to BD and p53(361-383), respectively whereas penta-L-Lysine was not effective at 240-fold higher molar concentration. The aggregation potential of basic peptides correlated with their ability to activate "latent" p53 for sequence specific DNA-binding in a band shift assay (cf. Fig. 2 and Table 1 ). To determine whether p53 can reverse aggregation, GST-p53 (37 nM) was added to aggregated DNA i.e. 5-8 min later than BD in incubation medium containing fluorescent oligonucleotide. In this experiment p53 was found to partially dissociate preformed aggregates (Fig. 6A, curve 5 ). Since dissociation of aggregated DNA may require energy and the nucleotide triphosphates GTP and ATP may regulate p53 interactions with DNA (16, 24), the effects of GTP and its analogs on p53-mediated DNA disaggregation were tested. GTP substantially potentiated the ability of GST-p53 to disaggregate DNA when GST-p53 (37 nM) was added to aggregate DNA, i.e. 5-8 min later than BD (A, compare curves 5 and 6). GST-p53 at 3.7 nM concentration did not prevent DNA aggregation induced by BD in the absence of GTP but strongly inhibited this reaction in the presence of GTP (B, curves 3 and 4); GST-p53 was added to the reaction mixture 5 min prior to BD in this experiment. Besides GST-p53, the wild type p53
protein, produced in bacteria, disaggregated DNA and GTP potentiated this reaction (data not shown). GDP, GMP and the nonhydrolyzable analog guanylyl-imidodiphosphate (GMPPNP) did not potentiate the ability of 3.7 nM of GST-p53
to inhibit DNA aggregation induced by BD (B, curves 5-7), and these compounds and GTP themselves had no influence on the Rh´-SO diffusion times (B, curves 8-11). GST-p53 (37 nM) also inhibited DNA aggregation by poly-L-Lysine (1.2 µM) in a GTP-potentiated manner (data not shown).
GST-p53His273, p53 protein with mutation in the core domain, did not inhibit DNA aggregation induced by BD (Fig. 6A, curve 7) . Preincubation of GSTp53 (12 nM) with PAb421 antibody (70 nM) for 30 min also reduced the ability of p53 to inhibit DNA aggregation induced by BD (data not shown). These findings suggest that the core and CTD of the full-length p53 are involved in DNA disaggregation. Since these domains in the form of individual proteins aggregated DNA (Fig. 5D , curves 5 and 6), they probably act in a cooperative fashion in fulllength p53 when p53 prevents DNA aggregation. p53, activated by BD or PAb421, bound a small fraction of radioactive BC oligonucleotide, containing specific p53 DNA binding sites, in a band shift assay (Fig. 2) . FCS was not, however, sufficiently sensitive to register this fraction in the presence of an excess (>90%) of unbound fluorescent oligonucleotide. The FCS data demonstrate that "latent"
p53 prevents the aggregation of most oligonucleotide molecules and releases them from aggregates. This reaction requires that p53 contacts the majority of oligonucleotide molecules in solution. Since no p53 complexes with Rh´-SO (Fig.   5D , curve 2) and basic peptides (Fig. 4 , curve 2) were found in these experiments, p53-DNA contacts were presumably short lasting.
Binding of latent p53 to long double-stranded DNA via the core and CTD - In order to identify the region in p53 that interacts with long DNAs, the binding of p53 domains to labeled ds 686 bp DNA fragment RD was analyzed.
Neither the GST-NTD nor the GST-protein alone gave rise to any complexes (Fig. 7B, lanes 2,3) . The activation of DNA-binding by basic peptides is not unique for p53 and has been suggested to be a general in vitro phenomenon, which applies to BZLF1, C/EBP and GAL4 (26) and YY1 (present study). The mechanism of activation has not been identified, although it was proposed that activating peptides themselves did not bind to DNA (26) . Liquid-crystalline DNA organization was observed in dinoflagellate chromosomes (33) and sperm cells (34) . Many proteins involved in DNA recombination can promote DNA aggregation, and the formation of hybrid DNA intermediates may be facilitated in DNA aggregates (35) . p53-mediated inhibition of DNA recombination
(1) may be based on its ability to inhibit DNA aggregation, a necessary event in DNA hybrid formation.
It has been shown that the nucleotide triphosphate GTP inhibits DNA renaturation and strand exchange catalyzed by p53 (16) and that ATP binds to p53 at its C-terminus (36) . Furthermore, the p53 DNA-binding function may be regulated by an ATP/ADP molecular switch and p53 has intrinsic ATPase and GTPase activities (24). We observed that only GTP, but not GDP, GMP and the nonhydrolyzable analog GMPPNP, potentiates the ability of p53 to disaggregate DNA. This suggests that DNA disaggregation induced by p53 is an energydependent process.
Binding of "latent"p53 to long but not to short DNA molecules -p53 may bind preferentially to long (247mer and longer) but not to short (30- is partially activated (37) . Our observation that p53, produced in bacteria, is latent for binding to the consensus sequences either in the presence or in the absence of non-specific DNA does not agree with the steric model of p53 latency.
Besides interaction with specific DNA sequences, p53 interacts via its core with internal segments of long ss and ds DNA (8, 17) , plasmid DNA damaged by ionizing radiation (38) , insertion/deletion lesions in DNA (39) (29) . Paradoxically, the full-length p53 capable of binding to long ss and ds DNA via the core domain (8, 17) was latent for binding to the consensus sites (7; present study). These observations seem to be in conflict with the two described models since none of them allows the interaction of the core of latent p53 with DNA.
In the absence of other satisfactory explanations of these contradictions, we suggest that CTD, when it binds to DNA, prevents the interaction of the core of the full-length p53 with specific, but not with nonspecific DNA sequences (see scheme 
